1. Forrer F, Fischer GF, Maas O, et al. Variations in radioiodine therapy in Europe: decision-making after total thyroidectomy. Oncology 2022;100:74-81.
2. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-133.
3. Tuttle RM, Ahuja S, Avram AM, et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid 2019;29:461-470.
4. 中国临床肿瘤学会甲状腺癌专业委员会,中国研究型医院学会分子诊断专业委员会甲状腺癌学组,医促会甲状腺疾病专业委员会核医学组,等.分化型甲状腺癌术后131I治疗前评估专家共识. 中国癌症杂志 2019;29:832-840.
5. Leboulleus S, Bournaud C, Chougnet CN, et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N Engl J Med 2022;386:923-932.
6. Avram AM, Rosculet N, Esfandiari NH, et al. Differentiated thyroid cancer outcomes aftersurgery and activity-adjusted 131I theragnostics. ClinNucl Med 2019;44:11-20.
7. Jin Y, Ruan M, Cheng L, et al. Radioiodine uptake and thyroglobulin-guided radioiodine remnant ablation in patients with differentiated thyroid cancer: a prospective, randomized, open-label, controlled trial. Thyroid 2019;29:101-110.
8. Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30:1856-1883.
9. Moon S, Song YS, Kim YA, et al. Effects of coexistent BRAFV600Eand TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta-analysis. Thyroid 2017;27:651-660.
